



AGENDA

HISTORY
COMPANY PROFILE
TECHNOLOGY AND SERVICES
SUMMARY



History of Richter-Helm - Owners Structure



Gedeon Richter Plc., Budapest, Hungary

- Richter sells APIs and finished form drugs to nearly 100 countries around the world
- Largest Hungarian pharmaceutical company, today
- Turnover in 2019 was 1,56 billion €





HELM AG, Hamburg, Germany

- World's leading independent chemicals and pharmaceuticals marketing enterprises
- Branches and sales offices in more than 30 countries
- HELM world-wide sales in 2019
 were 5.016 billion €

www.richter.hu

www.helmag.com



History of Richter-Helm

More than 30 years of experience in biopharmaceuticals production

Our development and production facilities



1987	Foundation of Pharma Biotechnologie Hannover & start of GMP production
1989	Entering in contract GMP manufacturing
1998	Building up of development centre in Hamburg
2000	Construction of the large scale GMP facility in Bovenau
2003	Initiation of GMP production in Bovenau
2007	Acquisition by Gedeon Richter Plc and
	HELM AG
2009	Fully remodelled Hannover facility in operation
2011	Successful implementation of P. pastoris technology
2013	FDA approval
2014	Major capacity enlargement in Bovenau
2018	FDA approval



Our development and production facilities






Hamburg

Headquarter & Development Center
Process Development
Quality Control & Quality Assurance
Business Development & Project
Management
Administration



Process Development
Analytical Development
Quality Assurance
Guidance



BovenauManufacturing Site up to 1500 L



Hannover
Manufacturing Site up to 300 L









Experience and Potential Products

Richter Helm is focused on microbial production.

Production in Bacteria

- Recombinant proteins (e.g. cytokines, growth factors, antibody fragments)
- Bacterial vaccines (e.g. attenuated whole cell vaccines)
- Plasmid DNA (e.g. gene therapy, vaccines, starting material for virus production)

Production in Yeast

 Recombinant proteins (e.g. enzymes, new antibody formats)





Complete Drug Substance Development & Manufacturing from one Source

Biopharmaceuticals Production Value Chain

Strain
Development/
Optimization

Process
Development/
Analytical
Development

Process Transfer/ Scale-up Clinical Trial Supply Phase I – III

Commercial production

Locations and Services

Development centre, Hamburg



- Strain development
- Process development
- Analytical method development incl. bioassay development
- · GMP compliant QC labs

GMP production plant,

Hannover



- GMP compliant multipurpose facility
- Manufacturing in up to 300 L fermenter scale
- 1000 m² production area
- Manufacturing license for proteins, DNA, vaccines and chemical conjugation

GMP production plant,

Bovenau




- GMP compliant multipurpose facility
- Manufacturing in up to 1500 L fermenter scale
- 4500 m² production area
- Manufacturing license for proteins, DNA and vaccines





Areas of Operation

Product classes by sales (since 2013)



Development Status of Manufactured Products by batches (since 2012)









■ Commercial



Audit and Accreditation History



T.C. Sağlık Bakanlığı



Employees










PROCESS DEVELOPMENT

SERVICES

- Strain development
- USP and DSP feasibility and optimization studies
- Development of fermentation and downstream processes
- Supply of preclinical materials
- Establishment of small-scale models
- Process characterization studies
- NOR and PAR studies
- Lifetime studies
- Impurity removal studies
- QbD and DoE experience

TECHNOLOGIES

- Various proprietary E.coli expression systems
- Bacteria and yeast cultivation
- Design of Experiments (DoE) modules
- Batch and fed-batch fermentation
- Cell harvesting by centrifugation, filtration, or TFF
- Broad refolding expertise
- Various conditioning technologies
- Ion-exchange, mixed-mode, HIC, RPC, and AF chromatography (FPLC, HPLC)







ANALYTICS

SERVICES

- Phase-dependent method development and validation
- Regulatory compliant method transfer
- Establishment of reference standards
- Formal stability studies (ICH)
- Supportive stability studies
- Cell bank characterization
- Comparability studies



TECHNOLOGIES

- pH, visual Inspection, osmolality
- UV/Vis spectrometry
- U/HPLC (SEC, RP, IEX)
- Capillary electrophoresis (iCE3)
- 1D gel electrophoresis (Coomassie Brilliant Blue, silver staining, blotting, IEF)
- HCP and DNA quantification by the threshold system
- Generic and process-specific HCP-ELISA
- Quantitative PCR (rDNA, RNA, copy number determination)
- Cell-based bioassay (various readouts)
- Immunoassays
- Kinetic assays (e.g. of endotoxins, enzymatic activity)
- Receptor binding assays
- Flow cytometry



PRODUCTION

PRODUCTION FACILITIES

- Two independent multiproduct facilities
- E.coli and yeast production systems
- Cell bank production (MCB and WCB)
- Fermenter volumes from 10 to 1.500 liters
- Flexible DSP scales
- Independent USP and DSP trains
- Technologies and equipment for biopharmaceutical production (e.g. methanol feeding for Pichia expression, preparative HPLC, large refolding vessels)
- Experience with diverse production technologies (e.g. enzymatic and chemical PEGylation, lowshear cell lysis, cell attenuation)
- A good balance of commercial and early phase projects

- Approved by all major regulatory bodies, including the FDA
- Well-established technology transfer procedures
- Person-in-plant (PIP) approach





QUALITY

QUALITY MEASURES AT A GLANCE

- Use of GMPs throughout every project: from clinical phases I, II, and III to commercial production, during manufacture, quality control, and storage of biotechnological intermediates, and drug substances
- Quality monitoring of all relevant processes
- A comprehensive quality manual



- A Document Management System for correct workflow, approval procedures and proper archiving of documents
- GMP certificate and manufacturing licenses from the responsible German authorities
- Facilities approved by regulatory bodies (including EMA, FDA, ANVISA, PMDA and MFDS)
- Five officially registered QPs



Summary

Expertise

- ✓ Strong track record in microbial production
- ✓ More than 30 years of experience in GMP production
- ✓ Trustful and continued customer relationships

Facilities

- ✓ GMP facilities approved by int. authorities
- ✓ Flexible production capabilities
- ✓ Extension of capacities planned

Customer Services

- ✓ Project Management
- ✓ Consultancy





